Radioligand Therapy Market Report: Trends, Forecast and Competitive Analysis to 2030
Lucintel has been in the business of market research and management consulting since 2000 and has published over 1000 market intelligence reports in various markets / applications and served over 1,000 clients worldwide. This study is a culmination of four months of full-time effort performed by Lucintel's analyst team. The analysts used the following sources for the creation and completion of this valuable report:
In-depth interviews of the major players in this market
Detailed secondary research from competitors’ financial statements and published data
Extensive searches of published works, market, and database information pertaining to industry news, company press releases, and customer intentions
A compilation of the experiences, judgments, and insights of Lucintel’s professionals, who have analyzed and tracked this market over the years.
Extensive research and interviews are conducted across the supply chain of this market to estimate market share, market size, trends, drivers, challenges, and forecasts. Below is a brief summary of the primary interviews that were conducted by job function for this report.
Thus, Lucintel compiles vast amounts of data from numerous sources, validates the integrity of that data, and performs a comprehensive analysis. Lucintel then organizes the data, its findings, and insights into a concise report designed to support the strategic decision-making process. The figure below is a graphical representation of Lucintel’s research process.
In-depth interviews of the major players in this market
Detailed secondary research from competitors’ financial statements and published data
Extensive searches of published works, market, and database information pertaining to industry news, company press releases, and customer intentions
A compilation of the experiences, judgments, and insights of Lucintel’s professionals, who have analyzed and tracked this market over the years.
Extensive research and interviews are conducted across the supply chain of this market to estimate market share, market size, trends, drivers, challenges, and forecasts. Below is a brief summary of the primary interviews that were conducted by job function for this report.
Thus, Lucintel compiles vast amounts of data from numerous sources, validates the integrity of that data, and performs a comprehensive analysis. Lucintel then organizes the data, its findings, and insights into a concise report designed to support the strategic decision-making process. The figure below is a graphical representation of Lucintel’s research process.
1. EXECUTIVE SUMMARY
2. GLOBAL RADIOLIGAND THERAPY MARKET : MARKET DYNAMICS
2.1: Introduction, Background, and Classifications
2.2: Supply Chain
2.3: Industry Drivers and Challenges
3. MARKET TRENDS AND FORECAST ANALYSIS FROM 2018 TO 2030
3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
3.2. Global Radioligand Therapy Market Trends (2018-2023) and Forecast (2024-2030)
3.3: Global Radioligand Therapy Market by Isotope
3.3.1: Fluorine –
3.3.2: Gallium -
3.3.3: Lutetium -
3.3.4: Others
3.4: Global Radioligand Therapy Market by Targeted Receptor
3.4.1: Prostate-specific Membrane Antigen
3.4.2: Somatostatin Receptor
3.4.3: Epidermal Growth Factor Receptor
3.4.4: Others
3.5: Global Radioligand Therapy Market by Indication
3.5.1: Prostate Cancer
3.5.2: Neuroendocrine Tumors
3.5.3: Breast Cancer
3.5.4: Others
3.6: Global Radioligand Therapy Market by End Use
3.6.1: Hospitals & Clinics
3.6.2: Diagnostic Centers
3.6.3: Others
4. MARKET TRENDS AND FORECAST ANALYSIS BY REGION FROM 2018 TO 2030
4.1: Global Radioligand Therapy Market by Region
4.2: North American Radioligand Therapy Market
4.2.2: North American Radioligand Therapy Market by End Use: Hospitals & Clinics, Diagnostic Centers, and Others
4.3: European Radioligand Therapy Market
4.3.1: European Radioligand Therapy Market by Isotope: Fluorine – 18, Gallium - 68, Lutetium - 177, and Others
4.3.2: European Radioligand Therapy Market by End Use: Hospitals & Clinics, Diagnostic Centers, and Others
4.4: APAC Radioligand Therapy Market
4.4.1: APAC Radioligand Therapy Market by Isotope: Fluorine – 18, Gallium - 68, Lutetium - 177, and Others
4.4.2: APAC Radioligand Therapy Market by End Use: Hospitals & Clinics, Diagnostic Centers, and Others
4.5: ROW Radioligand Therapy Market
4.5.1: ROW Radioligand Therapy Market by Isotope: Fluorine – 18, Gallium - 68, Lutetium - 177, and Others
4.5.2: ROW Radioligand Therapy Market by End Use: Hospitals & Clinics, Diagnostic Centers, and Others
5. COMPETITOR ANALYSIS
5.1: Product Portfolio Analysis
5.2: Operational Integration
5.3: Porter’s Five Forces Analysis
6. GROWTH OPPORTUNITIES AND STRATEGIC ANALYSIS
6.1: Growth Opportunity Analysis
6.1.1: Growth Opportunities for the Global Radioligand Therapy Market by Isotope
6.1.2: Growth Opportunities for the Global Radioligand Therapy Market by Targeted Receptor
6.1.3: Growth Opportunities for the Global Radioligand Therapy Market by Indication
6.1.4: Growth Opportunities for the Global Radioligand Therapy Market by End Use
6.1.5: Growth Opportunities for the Global Radioligand Therapy Market by Region
6.2: Emerging Trends in the Global Radioligand Therapy Market
6.3: Strategic Analysis
6.3.1: New Product Development
6.3.2: Capacity Expansion of the Global Radioligand Therapy Market
6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Radioligand Therapy Market
6.3.4: Certification and Licensing
7. COMPANY PROFILES OF LEADING PLAYERS
7.1: Novartis
7.2: POINT Biopharma Global
7.3: Molecular Partners
7.4: Telix Pharmaceuticals
7.5: Fusion Pharma
7.6: Lantheus Holdings
7.7: Curium
7.8: Precrix
7.9: Orano
7.10: Artios Pharma
2. GLOBAL RADIOLIGAND THERAPY MARKET : MARKET DYNAMICS
2.1: Introduction, Background, and Classifications
2.2: Supply Chain
2.3: Industry Drivers and Challenges
3. MARKET TRENDS AND FORECAST ANALYSIS FROM 2018 TO 2030
3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
3.2. Global Radioligand Therapy Market Trends (2018-2023) and Forecast (2024-2030)
3.3: Global Radioligand Therapy Market by Isotope
3.3.1: Fluorine –
3.3.2: Gallium -
3.3.3: Lutetium -
3.3.4: Others
3.4: Global Radioligand Therapy Market by Targeted Receptor
3.4.1: Prostate-specific Membrane Antigen
3.4.2: Somatostatin Receptor
3.4.3: Epidermal Growth Factor Receptor
3.4.4: Others
3.5: Global Radioligand Therapy Market by Indication
3.5.1: Prostate Cancer
3.5.2: Neuroendocrine Tumors
3.5.3: Breast Cancer
3.5.4: Others
3.6: Global Radioligand Therapy Market by End Use
3.6.1: Hospitals & Clinics
3.6.2: Diagnostic Centers
3.6.3: Others
4. MARKET TRENDS AND FORECAST ANALYSIS BY REGION FROM 2018 TO 2030
4.1: Global Radioligand Therapy Market by Region
4.2: North American Radioligand Therapy Market
4.2.2: North American Radioligand Therapy Market by End Use: Hospitals & Clinics, Diagnostic Centers, and Others
4.3: European Radioligand Therapy Market
4.3.1: European Radioligand Therapy Market by Isotope: Fluorine – 18, Gallium - 68, Lutetium - 177, and Others
4.3.2: European Radioligand Therapy Market by End Use: Hospitals & Clinics, Diagnostic Centers, and Others
4.4: APAC Radioligand Therapy Market
4.4.1: APAC Radioligand Therapy Market by Isotope: Fluorine – 18, Gallium - 68, Lutetium - 177, and Others
4.4.2: APAC Radioligand Therapy Market by End Use: Hospitals & Clinics, Diagnostic Centers, and Others
4.5: ROW Radioligand Therapy Market
4.5.1: ROW Radioligand Therapy Market by Isotope: Fluorine – 18, Gallium - 68, Lutetium - 177, and Others
4.5.2: ROW Radioligand Therapy Market by End Use: Hospitals & Clinics, Diagnostic Centers, and Others
5. COMPETITOR ANALYSIS
5.1: Product Portfolio Analysis
5.2: Operational Integration
5.3: Porter’s Five Forces Analysis
6. GROWTH OPPORTUNITIES AND STRATEGIC ANALYSIS
6.1: Growth Opportunity Analysis
6.1.1: Growth Opportunities for the Global Radioligand Therapy Market by Isotope
6.1.2: Growth Opportunities for the Global Radioligand Therapy Market by Targeted Receptor
6.1.3: Growth Opportunities for the Global Radioligand Therapy Market by Indication
6.1.4: Growth Opportunities for the Global Radioligand Therapy Market by End Use
6.1.5: Growth Opportunities for the Global Radioligand Therapy Market by Region
6.2: Emerging Trends in the Global Radioligand Therapy Market
6.3: Strategic Analysis
6.3.1: New Product Development
6.3.2: Capacity Expansion of the Global Radioligand Therapy Market
6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Radioligand Therapy Market
6.3.4: Certification and Licensing
7. COMPANY PROFILES OF LEADING PLAYERS
7.1: Novartis
7.2: POINT Biopharma Global
7.3: Molecular Partners
7.4: Telix Pharmaceuticals
7.5: Fusion Pharma
7.6: Lantheus Holdings
7.7: Curium
7.8: Precrix
7.9: Orano
7.10: Artios Pharma
